Evommune, Inc.
No SEC Form 4 filings for $EVMN in the last 30 days.
Evommune, Inc. (EVMN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 evmn-ex99_1.htm EX-99.1 EX-99.1 Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights ‑ Company to announce EVO756 atopic dermatitis (AD) Phase 2b top-line data in September 2026 ‑ EVO756 migraine prophylaxis Phase 2b dose-ranging trial
Carver Kyle (Chief Financial Officer) purchased 1,000 shares of Evommune, Inc. (EVMN) at $13.26 on 2026-07-08.
A roundup of July 8, 2026 insider trades reported major buys in Mission Produce (AVO), where Globalharvest Holdings Venture Ltd bought 650,415 shares for about $8.28M at $12.73 avg, and Boundless Bio (BOLD), where Tang Capital bought 57,210 shares for about $141.9K. Major sells included Rocket Lab (RKLB) CEO Peter Beck selling about $286.4M and Dell (DELL) director Egon Durban/Silver Lake selling about $29.9M.
Over the past 7 days, alphai's AI scored 1 news story mentioning EVMN (Evommune, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent EVMN coverage spans insider activity, financial news and earnings.
Near-term catalyst is September 2026 AD Phase 2b top-line data for EVO756; longer-dated catalysts include migraine Phase 2b top-line in 2027 and EVO301 Phase 2a conference presentation.
This is a small insider buy with limited standalone signal, but it can modestly support near-term sentiment if traders treat it as confidence.
Director buy while the stock trades near its 52-week low is a contrarian sentiment signal.
A director open-market buy can be a modest bullish signal, but the filing provides no new company fundamentals or guidance.
The stock’s sharp drop is tied to the Phase 2b failure, while the law-firm probe adds incremental overhang around potential insider-information issues.
alphai scores every news story that mentions EVMN with an AI model for sentiment and relevance, and aggregates insider trades from Evommune, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Evommune, Inc. (EVMN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 evmn-ex99_1.htm EX-99.1 EX-99.1 Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights ‑ Company to announce EVO756 atopic dermatitis (AD) Phase 2b top-line data in September 2026 ‑ EVO756 migraine prophylaxis Phase 2b dose-ranging trial
4 min readCarver Kyle (Chief Financial Officer) purchased 1,000 shares of Evommune, Inc. (EVMN) at $13.26 on 2026-07-08.
1 min readA roundup of July 8, 2026 insider trades reported major buys in Mission Produce (AVO), where Globalharvest Holdings Venture Ltd bought 650,415 shares for about $8.28M at $12.73 avg, and Boundless Bio (BOLD), where Tang Capital bought 57,210 shares for about $141.9K. Major sells included Rocket Lab (RKLB) CEO Peter Beck selling about $286.4M and Dell (DELL) director Egon Durban/Silver Lake selling about $29.9M.
7 min readKIRSCH ARTHUR S purchased 10,000 indirectly-held shares of Evommune, Inc. (EVMN) at $13.30 ($0.13M total) on 2026-07-07.
2 min readLevi & Korsinsky said it is investigating Evommune, Inc. (NYSE: EVMN) after its lead drug EVO756 failed a Phase 2b primary endpoint, which the company said led to about a 38% share drop. The firm cites CEO Luis Pena and CSO Jeegar Patel sales/exercises on June 22, 2026 under Rule 10b5-1 plans before the disclosure.
5 min readA roundup of analysts’ June 30 price-target changes across many stocks. Examples: Wells Fargo raised AAL to $17 from $12; Leerink raised ABVX to $148 from $140; JPMorgan cut ACI to $20 from $22; Jefferies cut ALB to $211 from $244; Goldman cut APA to $32 from $34; KeyCorp raised ATI to $211 from $175.
2 min readCohen David E sold 600 shares of Evommune, Inc. (EVMN) at $21.38 on 2026-06-02 under a Rule 10b5-1 trading plan.
2 min readCohen David E sold 5,456 shares of Evommune, Inc. (EVMN) at $20.21 ($0.11M total) on 2026-06-02 under a Rule 10b5-1 trading plan.
2 min readPatel Jeegar Pravinkumar (Chief Scientific Officer) sold 16,687 shares of Evommune, Inc. (EVMN) at $22.74 ($0.38M total) on 2026-06-01 under a Rule 10b5-1 trading plan.
3 min readPena Luis C. (President & CEO) sold 16,787 shares of Evommune, Inc. (EVMN) at $22.74 ($0.38M total) on 2026-06-01 under a Rule 10b5-1 trading plan.
2 min read
